毛盈颖，博士，教授，硕士生导师，流行病学教研室主任。浙江省万人计划“青年拔尖人才”、浙江省高校领军人才培养计划“高层次拔尖人才”、浙江省“院士结对青年英才”、浙江省科协“育才工程”培养对象、浙江中医药大学5151远志人才。2009年毕业于四川大学，获预防医学、英语双学士学位，2009年至2014年在浙江大学成功彩票注册攻读流行病学专业博士，2010年至2012年在美国耶鲁大学成功彩票注册环境卫生系联合培养。2014年进入浙江中医药大学工作，2019年晋升副教授，2022年晋升教授。主要致力于慢性非传染性疾病分子流行病学研究。先后获得国家自然科学基金3项，省自然科学基金2项，省医药卫生科技计划、省民政厅政策理论课题等多项资助。目前累计发表学术论文100余篇。
研究方向：
1.慢性非传染性疾病分子流行病学
联系方式：
地址：杭州市滨江区滨文路548号
电话：0571-86619230
邮箱：myy@zcmu.edu.cn
主要科研项目：
1．从肠道菌群调控GDF15探讨解毒祛瘀滋阴方治疗系统性红斑狼疮的作用机制，国家自然科学基金面上项目（82174208，2022.01-2025.12,54万元），主持
2．TLR4遗传变异与肠道菌群交互作用在AS发生发展中的初探及运脾益肾通督方干预研究，国家自然科学基金面上项目（81973663，2020.01-2023.12，55万元），主持。
3．血清chemerin水平与结直肠癌及其癌前病变发生风险的分子流行病学研究，国家自然科学基金青年项目（81602917，2017.01-2019.12，18万元），主持
4．TLR2遗传变异与肠道菌群交互作用在强直性脊柱炎发生中的初探，浙江省自然科学基金一般探索项目（LY22H260005，2022.01-2024.12，10万元），主持
5．结直肠癌高发区人群癌前病变的血浆MEG3甲基化筛检分子标志物研究，浙江省自然科学基金青年项目（LQ15H260001，2015.01-2017.12，5万元），主持
代表性论文：
1. Jie Song#, Aole Li#, Yu Qian, Bin Liu, Linshuoshuo Lv, Ding Ye, Xiaohui Sun*, Yingying Mao*. Genetically predicted circulating levels of cytokines and the risk of cancer. Frontiers in Immunology, 2022, 13: 886144. PMID: 35865545. (IF=8.787, 二区TOP)
2. Bin Liu, Ding Ye, Hong Yang, Jie Song, Xiaohui Sun, Yingying Mao*, Zhixing He*. Two-sample Mendelian randomization analysis investigates causal associations between gut microbial genera and inflammatory bowel disease, and specificity causal associations in ulcerative colitis or crohn’s disease. Frontiers in Immunology, 2022, 13:921546. PMID: 35860271. (IF=8.787, 二区TOP)
3. Linshuoshuo Lv#, Ding Ye#, Jie Chen, Yu Qian, Alan Nuo Fu, Jie Song, Hong Yang, Bin Liu, Xiaohui Sun, Lingbing Du, Yingying Mao*. Circulating phosphorus concentration and risk of prostate cancer: a Mendelian randomization study. American Journal of Clinical Nutrition, 2022, 115(2): 534-543. PMID: 34617559. (IF=8.472,一区TOP)
4. Xiaohui Sun#, Bin Liu#, Sitong Liu, David JH Wu, Jianming Wang, Yi Qian, Ding Ye*, Yingying Mao*. Sleep disturbance and psychiatric disorders: a bidirectional Mendelian randomization study. Epidemiology and Psychiatric Sciences, 2022, 13: e26: 35465862. PMID: 35465862. (IF=7.818, 一区TOP)
5. Xiaohui Sun#, Bin Liu#, Ying Chen, Linshuoshuo Lv, Ding Ye*, Yingying Mao*. Modifiable risk factors for intracranial aneurysms: evidence from genetic studies. International Journal of Stroke, 2022, 17(10): 1107-1113. PMID: 36408635. (IF=6.948, 二区)
6. Shaoxue Yang#, Jie Song#, Hong Yang, Wei Liu, Yuqing Jiang, Xiaohui Sun, Ding Ye, Xiaosong Xu*, Yingying Mao*. Genetically predicted circulating concentrations of alanine and alanine aminotransferase were associated with prostate cancer risk. Clinical Epidemiology, 2022, 14:1255-1264. (IF=5.814, 二区)
7. Xiaohui Sun, Ding Ye, Mengting Jiang, Yu Qian, Yingying Mao*. Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer. Sleep, 2021, 44(10): zsab104. PMID: 33878190. (IF=6.313, 二区TOP)
8. Ding Ye, Bin Liu, Zhixing He, Lin Huang, Yu Qian, Keding Shao, Chengping Wen*, Yingying Mao*. Assessing the associations of growth differentiation factor 15 with rheumatic diseases using genetic data. Clinical Epidemiology, 2021,13: 245-252. PMID: 33790654. (IF=5.814, 三区)
9. Yu Qian#, Ding Ye#, Huijun Huang, David JH Wu, Yaxuan Zhuang, Jiang Xia, Yingying Mao*. Coffee consumption and risk of stroke: a Mendelian randomization study. Annals of Neurology, 2020, 87(4): 525-532. PMID: 32034791. (IF=10.422, 一区TOP)
10. Zhen Zeng#, Wanting Zhang#, Yu Qian#, Huijun Huang, David JH Wu, Zhixing He, Ding Ye, Yingying Mao*, Chengping Wen. Association of telomere length with risk of rheumatoid arthritis: a meta-analysis and Mendelian randomization. Rheumatology (Oxford), 2020, 59(5):940-947. PMID: 31697380. (IF=7.58, 二区)
11. Xiaohui Sun, Ding Ye, Yu Qian, Lingbin Du, Xia Jiang*, Yingying Mao*. Genetically predicted levels of circulating cytokines and prostate cancer risk: A Mendelian randomization study. International Journal of Cancer, 2020, 147(9):2469-2478. PMID: 33460126. (IF=7.396, 二区TOP)
12. Chiyu He#, Yu Qian#, Bin Liu, Shaoxue Yang, Ding Ye, Xiaohui Sun, Tianhui Chen*, Yingying Mao*. Genetically predicted circulating level of C-reactive protein is not associated with prostate cancer risk. Frontiers in Oncology, 2020, 10: 545603. PMID: 33178578. (IF=6.224, 二区)
